title: Haemodialysis hypotension and nitric oxide production: comparison of heparin with parnaparin.
abstract: BACKGROUND
  There is increasing evidence for the role of nitric oxide (NO) in haemodialysis hypotension but the source of elevated NO is still controversial. Heparin has been reported to enhance NO production by cultured human endothelial cells. The aim of this study was to compare the role of unfractionated heparin and low molecular weight heparin (LMWH, parnaparin) on mean arterial pressure (MAP) and NO production in haemodialysis patients with hypotensive episodes.
  
  
  METHODS
  Ten maintenance haemodialysis patients with hypotensive episodes were involved in this study. Patients were anticoagulated with heparin for 3 weeks and then switched to parnaparin for 3 weeks. Serum NO levels were analysed before starting dialysis, at the nadir of MAP during a haemodialysis session and at the end of dialysis in the last haemodialysis session of the 3rd week of each anticoagulation treatment.
  
  
  RESULTS
  NO levels were 39.4 +/- 13.2 microM at the beginning of haemodialysis, 92.4 +/- 31.4 microM during hypotensive episode and 43.1 +/- 25.1 microM at the end of dialysis with heparin treatment (p < 0.05). In the parnaparin period, NO levels were 47.2 +/- 22.7 microM at the beginning, 80.7 +/- 46.5 microM during the hypotensive episode and 45.8 +/- 23.2 microM at the end of the session (p < 0.05). The percent increase in NO levels during the hypotensive period compared to that at the beginning of haemodialysis with heparin was significantly higher than that with parnaparin (140.2 +/- 50.4 vs. 119.6 +/- 44.8%; p < 0.05). The percent decrease in MAP with heparin use was also significantly higher than with parnaparin use (48.6 +/- 6.4 vs. 39.6 +/- 5.3%; p < 0.05).
  
  
  CONCLUSIONS
  We have observed that MAP decrements and NO increases were less manifest during hypotensive episodes with parnaparin treatment compared to heparin. This difference may be related to differences in endothelial binding capacity, thrombin affinity and/or effects on platelet functions of unfractionated heparin and LMWHs.
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Arici
authors.forename: Bülent
authors.initials: B
authors.lastname: Altun
authors.forename: Ozkan
authors.initials: O
authors.lastname: Dinler
authors.forename: Ahmet A
authors.initials: AA
authors.lastname: Kiykim
authors.forename: Celalettin
authors.initials: C
authors.lastname: Usalan
authors.forename: Yunus
authors.initials: Y
authors.lastname: Erdem
authors.forename: Unal
authors.initials: U
authors.lastname: Yasavul
authors.forename: Cetin
authors.initials: C
authors.lastname: Turgan
authors.forename: Sali
authors.initials: S
authors.lastname: Cağlar
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007022:Hypotension / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000096:biosynthesis* / Q000502:physiology; D006435:Renal Dialysis / Q000009:adverse effects*; D051437:Renal Insufficiency / Q000628:therapy
chemical_list: D006495:Heparin, Low-Molecular-Weight; D009569:Nitric Oxide; D006493:Heparin; C080945:parnaparin